Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date
Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), a pioneering biotech developing innovative treatments for common and rare cardiovascular diseases, announced on November 17, 2023, that the Board of Directors of the Company had decided to enter into a loan agreement of up to SEK 90 million issued by Formue Nord Fokus A/S, renamed to Fenja Capital II A/S (“Fenja Capital”), which matures for payment on May 14, 2025. Cereno Scientific announces today, July 10, 2024, that the Board of Directors of the Company has decided to extend financial runway through loan maturity date